Loading institutional data...
Loading institutional data...
Held by 168 of 5,944 reporting institutions (90th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$163M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -917%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $111M covers the $0 due within a year 110745000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-18
Where each multiple sits in its own 9-yr range · 56th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 9-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 1.4× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 159.8 | — | 8.6 | 10.7 | 11.9 | 11.3 | 9.8 | 11.3 |
| Gross Profit | -59.8 | 100.0 | 91.4 | 89.3 | 88.1 | 88.7 | 90.2 | 88.7 |
| R&D | 3274.3 | 273872.2 | 401.0 | 99.2 | 82.2 | 55.1 | 63.2 | 61.1 |
| SG&A | 3508.1 | 334438.9 | 764.6 | 182.2 | 128.7 | 112.8 | 134.0 | 141.3 |
| Operating Income | -6842.2 | -608211.1 | -1074.2 | -192.1 | -122.8 | -79.2 | -107.1 | -113.7 |
| Income Tax | 11.1 | — | 28.6 | 3.0 | 2.7 | 4.7 | 3.1 | 0.1 |
| Net Income | -6707.2 | -584144.4 | -1088.9 | -230.7 | -170.6 | -123.6 | -140.4 | -139.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on URGN: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109.8M 100.0% | $90.4M 100.0% | $82.7M 100.0% | $64.4M 100.0% | $48.0M 100.0% | $11.8M 100.0% | $18K 100.0% | $1.1M 100.0% | $8.2M 100.0% | $17.5M 100.0% |
| Cost of Revenue | $12.4M 11.3% | $8.9M 9.8% | $9.4M 11.3% | $7.7M 11.9% | $5.2M 10.7% | $1.0M 8.6% | — | $1.8M 159.8% | $600K 7.4% | $28K 0.2% |
| Gross Profit | $97.3M 88.7% | $81.5M 90.2% | $73.4M 88.7% | $56.7M 88.1% | $42.9M 89.3% | $10.8M 91.4% | $18K 100.0% | -$675K -59.8% | $7.6M 92.6% | $17.5M 99.8% |
| Research & Development | $67.1M 61.1% | $57.1M 63.2% | $45.6M 55.1% | $52.9M 82.2% | $47.6M 99.2% | $47.3M 401.0% | $49.3M 273872.2% | $36.9M 3274.3% | $18.7M 229.2% | — |
| Selling, General & Admin | $155.1M 141.3% | $121.2M 134.0% | $93.3M 112.8% | $82.8M 128.7% | $87.5M 182.2% | $90.2M 764.6% | $60.2M 334438.9% | $39.6M 3508.1% | $8.8M 108.0% | $6.4M 36.6% |
| Total Operating Expenses | — | — | — | — | — | — | $109.5M 608311.1% | $76.5M 6782.4% | $27.5M 337.2% | — |
| Operating Income | -$124.9M -113.7% | -$96.8M -107.1% | -$65.5M -79.2% | -$79.0M -122.8% | -$92.3M -192.1% | -$126.7M -1074.2% | -$109.5M -608211.1% | -$77.2M -6842.2% | -$19.9M -244.5% | $798K 4.6% |
| Interest & Investment Income | $6.0M 5.4% | $8.9M 9.8% | $2.6M 3.2% | $938K 1.5% | $365K 0.8% | $2.0M 16.8% | $4.6M 25644.4% | — | — | — |
| Other Income (Expense), net | -$670K -0.6% | -$229K -0.3% | $838K 1.0% | $72K 0.1% | -$153K -0.3% | — | -$284K -1577.8% | -$124K -11.0% | $12K 0.1% | — |
| Pretax Income | -$153.4M -139.7% | -$124.0M -137.2% | -$98.3M -118.9% | -$108.0M -167.9% | -$109.4M -227.7% | -$125.1M -1060.3% | -$105.1M -584144.4% | -$75.5M -6696.1% | -$20.0M -244.9% | -$1.9M -11.1% |
| Income Tax Expense | $78K 0.1% | $2.8M 3.1% | $3.9M 4.7% | $1.8M 2.7% | $1.4M 3.0% | $3.4M 28.6% | — | $125K 11.1% | $19K 0.2% | — |
| Net Income | -$153.5M -139.8% | -$126.9M -140.4% | -$102.2M -123.6% | -$109.8M -170.6% | -$110.8M -230.7% | -$128.5M -1088.9% | -$105.1M -584144.4% | -$75.7M -6707.2% | -$20.0M -245.2% | -$1.9M -11.1% |
| Per Share | ||||||||||
| EPS (Basic) | $-3.19 | $-2.96 | $-3.55 | $-4.81 | $-4.96 | — | — | — | — | — |
| Weighted Avg Shares (Basic) | 48.1M | 42.9M | 28.8M | 22.8M | 22.3M | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| URGN | $2.1B | — | — | 19.1× | 21.4% | 88.7% | -140% | 146% | -917% | -1.0× | 168 |
Peers = companies sharing URGN's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.